Controlled Drug Delivery Approaches for Rheumatoid Arthritis Arthritis

Kaur, Amandeep; Harikumar, S. L.
August 2012
Journal of Applied Pharmaceutical Science;Aug2012, Vol. 2 Issue 8, p21
Academic Journal
A cure for rheumatoid arthritis is yet to be discovered. Although vast resources have been expended in the search for an immunological key to switch off the rheumatoid process, the most significant advances in the treatment of rheumatoid arthritis in recent times had come from gaining better understanding and skill in the safe use of existing disease modifying antirheumatic drugs (DMARDs). If prescribed appropriately and combined with adequate patient education and monitoring, Disease modifying anti-rheumatic drugs are safe and effective tools in the treatment of rheumatoid arthritis. The step down approach has been proposed for the treatment of patients with recent onset rheumatoid arthritis who have clinical features predictive of an adverse prognosis. More efficient 'targeting' of drugs at the site of desired action should help to minimize the adverse effects of therapy. Ultimately the most efficient way of relieving pain and stiffness will be to prevent or suppress the inflammatory disorders which give rise to the symptoms. Unfortunately this is a goal at present.


Related Articles

  • Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies. Mahfouz, Tarek M.; Kinder, David H. // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Apr2011, Vol. 10 Issue 2, p85 

    No abstract available.

  • ICAM-1 Targeted Nanogels Loaded with Dexamethasone Alleviate Pulmonary Inflammation. Coll Ferrer, M. Carme; Shuvaev, Vladimir V.; Zern, Blaine J.; Composto, Russell J.; Muzykantov, Vladimir R.; Eckmann, David M. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Lysozyme dextran nanogels (NG) have great potential in vitro as a drug delivery platform, combining simple chemistry with rapid uptake and cargo release in target cells with “stealth” properties and low toxicity. In this work, we study for the first time the potential of targeted NG...

  • Rheumatoid arthritis: Update on the newest DMARDs and their potential place in therapy. Schrand, Linda M.; Tuetken, Rebecca // Formulary;Jun2002, Vol. 37 Issue 6, p301 

    Examines the efficacy of disease modifying antirheumatic drugs (DMARDs) on treating rheumatoid arthritis (RA). Generic names of DMARDs; Contents of DMARDs; Symptoms and diagnosis of RA. INSETS: Table 1;Table 2.

  • Treatment for rheumatoid arthritis in adults. ROSE, VERNA L. // American Family Physician;12/1/1998, Vol. 58 Issue 9, p2178 

    Introduces the Leflunomide (Arava) anti-rheumatoid arthritis drug. Mechanism of action; Efficacy of the drug; Side effects.

  • Drugs for rheumatoid arthritis.  // Consumer Reports on Health;Jun96, Vol. 8 Issue 6, p65 

    Reports on the prescription of slow-acting antirheumatic drugs for the first diagnosis of rheumatoid arthritis.

  • Rheumatoid arthritis.  // Geriatrics;Dec98, Vol. 53 Issue 12, p16 

    Announces that etanercept (Enbrel) was approved for use in the reduction of signs and symptoms of active rheumatoid arthritis (RA) in patients who have an inadequate response to one or more of the antirheumatic agents. How etanercept can be used; Most common adverse effect; When therapy should...

  • New Drug for RA Available. Siegfried, Donna // Arthritis Today;Mar/Apr2003, Vol. 17 Issue 2, p41 

    Reports on the release of adalimumab Humira for the treatment of rheumatoid arthritis. Mechanism of action; Details on its clinical trials; Manufacturer of the drug.

  • Formulation and Evaluation of Sustained Release Tablets of Aceclofenac using Hydrophilic Matrix System. Kannan, Subramaniam; Manivannan, Rangasamy; Ganesan, Kugalur; Nishad, Parthiban Kakkatummal; Kumar, Natesan Senthil // International Journal of PharmTech Research;Jul-Sep2010, Vol. 2 Issue 3, p1775 

    The objective of the present study was to develop "once daily" sustained release tablets of Aceclofenac (200mg) by wet granulation using hydrophilic polymer like Hydroxy propyl methyl cellulose K -100. The drug excipient mixtures were subjected to preformulation studies. The tablets were...

  • Development and Characterization of Poly-e-Caprolactone Based Microspheres-A Sustained Drug Delivery System for Treating Rheumatoid Arthritis. SHANMUGAM, SARANYA; ANJU, T.; VELUSWAMY, PANDIYARASAN; BETALA, S. ANKITA; SINGH, CHARU PRIYA; SINGH, SHIVANI // Asian Journal of Chemistry;2013 Supplement, Vol. 25, pS333 

    Rheumatoid arthritis is an autoimmune disorder with a characteristic feature of chronic inflammation of the joints. This disease can also cause inflammation and injury in other organs in the body, but principally attacks flexible (synovial) joints. The commonly prescribed medication for this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics